C6001001 - A Study to Learn about the Study Medicine PF-08052667 in People with Bladder Cancer.

2025-521756-39-00 Protocol C6001001 Human pharmacology (Phase I) - First administration to humans Authorised, recruiting

Start 9 Apr 2026 · Status Authorised, recruiting · 2 EU/EEA countries · 5 sites · Protocol C6001001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Authorised, recruiting
Participants planned 222
Countries 2
Sites 5

Non-muscle invasive bladder cancer (NMIBC)

Key facts

Sponsor
Pfizer Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
9 Apr 2026 → ongoing
Decision date (initial)
2026-03-02
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2025-521756-39-00
ClinicalTrials.gov
NCT07206225

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Non-muscle invasive bladder cancer (NMIBC)

VersionLevelCodeTermSystem organ class
25.0 LLT 10087211 Non-muscle invasive bladder cancer 100000004848

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Pfizer Inc.

Sponsor organisation
Pfizer Inc.
Address
66 Hudson Boulevard East
City
New York
Postcode
10001-2189
Country
United States

Scientific contact point

Organisation
Pfizer Inc.
Contact name
Clinical Medical Lead

Public contact point

Organisation
Pfizer Inc.
Contact name
Clinical Medical Lead

Locations

2 EU/EEA countries · 5 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Authorised, recruiting 11 2
Spain Ongoing, recruiting 11 3
Rest of world
United States, Japan, United Kingdom, Israel, China, Korea, Republic of
200

Investigational sites

France

2 sites · Authorised, recruiting
Assistance Publique Hopitaux De Paris
Urologie, 43 Boulevard De L Hopital, 75013, Paris
Institut Gustave Roussy
Oncology, 114 Rue Edouard Vaillant, 94800, Villejuif

Spain

3 sites · Ongoing, recruiting
Hospital De La Santa Creu I Sant Pau
oftalmologia & oncologia, Carrer De San Quinti 89, 08041, Barcelona
Fundacio Puigvert
Oncologia, Calle De Cartagena 340-350, 08025, Barcelona
Hospital Universitario 12 De Octubre
Oncologia, Avenida De Cordoba Sn, 28041, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2026-04-24
Spain 2026-04-09 2026-05-08

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-10-23 Spain Acceptable with conditions
2026-02-26
2026-03-02